These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16321824)

  • 1. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
    Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
    Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
    Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
    Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
    Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
    Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
    Lim SH; Bailey-Wood R
    Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
    Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
    Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
    Kim SB; Baskar S; Kwak LW
    Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
    Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
    Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
    Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
    Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
    Foglietta M; Neelapu SS; Kwak LW; Jiang Y; Nattamai D; Lee ST; Fowler DH; Sportes C; Gress RE; Steinberg SM; Vence LM; Radvanyi L; Dwyer KC; Qazilbash MH; Bryant RN; Bishop MR
    Bone Marrow Transplant; 2013 Feb; 48(2):269-77. PubMed ID: 22773122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
    Neelapu SS; Baskar S; Kwak LW
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
    Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
    Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.